A total of 23 biopharmaceutical producers have committed capital to the vehicle, which will provide funding for the creation of new antibiotics.
Switzerland-based investment fund Antimicrobial Resistance (AMR) Action Fund has launched with almost $1bn in capital from biopharmaceutical companies to invest in developers of new antibiotics. AMR Action Fund is intended to operate as a partnership between 23 biopharmaceutical companies with the aim of bringing two to four new antibiotics to market by 2030. It is…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.